BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

GILD upcoming catalysts

Gilead Sciences: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 13 readout(s) and 5 FDA event(s). Subscribe to GILD (.ics).

Drugs: Sacituzumab Govitecan-hziy, Lenacapavir, Gemcitabine, Emtricitabine/tenofovir disoproxil fumarate, Eribulin Mesylate, Capecitabine Product, Vinorelbine, Tilpisertib Fosmecarbil, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Carboplatin

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Gilead Sciences GILDNCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Metastatic Breast Canceractive not recruiting331
2027-01 est.P2Gilead Sciences GILDNCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisactive not recruiting176
2027-02 est.P3Gilead Sciences GILDNCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally AdTriple Negative Breast Cancer; PD-L1 Positiveactive not recruiting443

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-08-27FDA approvalapprovedGILEAD SCIENCES INC GILDBIXLENVOApproved 2026-08-27: BIXLENVO (NDA221104 ORIG1)
2026-08-27FDA approvalapprovedGILEAD SCIENCES INC GILDBIXLENVO SUNLENCA STARTER PACKApproved 2026-08-27: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) (NDA221443 ORIG1)
2026-08-27FDA approvalapprovedGILEAD SCIENCES INC GILDSUNLENCAApproved 2026-08-27: SUNLENCA (NDA215973 SUPPL24)
2026-08-27FDA approvalapprovedGILEAD SCIENCES INC GILDSUNLENCAApproved 2026-08-27: SUNLENCA (NDA215974 SUPPL17)
2026-05-22FDA approvalapprovedGILEAD SCIENCES INC GILDHEPCLUDEXApproved 2026-05-22: HEPCLUDEX (BLA761468 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-03P2/P3Gilead Sciences GILDNCT06544733 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuHIV-1-Infectionterminated80
2026-10-27P2Gilead Sciences GILDNCT02932150 Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionChronic Hepatitis Bactive not recruiting150
2026-10 est.P2Gilead Sciences GILDNCT05119907 Study of Sacituzumab Govitecan in Patients With Solid TumorSolid Tumoractive not recruiting53
2026-07-27P2Gilead Sciences GILDNCT06101342 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting181
2026-07-22P2Gilead Sciences GILDNCT06101329 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting253
2026-05-28P2Gilead Sciences GILDNCT06513312 Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)Pre-Exposure Prophylaxis of HIV Infectionactive not recruiting268
2026-05-06P3Gilead Sciences GILDNCT06060665 Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)Primary Biliary Cholangitiscompleted96
2026-04-23P3Gilead Sciences GILDNCT06630299 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1HIV-1-Infectionactive not recruiting600
2026-04-17P3Gilead Sciences GILDNCT06630286 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-HIV-1-infectionactive not recruiting609
2026-03-16P2/P3Gilead Sciences GILDNCT06613685 Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedHIV-1-infectionterminated73
2026-03-04P2Gilead Sciences GILDNCT06290934 Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisactive not recruiting228
2025-12-17P2Gilead Sciences GILDNCT05629208 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)Cutaneous Lupus Erythematosus (CLE)terminated20
2025-12 est.P2Gilead Sciences GILDNCT06682234 Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus DiseaseFilovirus Disease; Postexposure Prophylaxis for Filovirus Diseasewithdrawn

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.